

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

PCT/ SE 03 / 0 0 3 7 7

REC'D 18 MAR 2003

WIPO

PCT

## Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer 0200657-5  
Patent application number

(86) Ingivningsdatum 2002-03-04  
Date of filing

Stockholm, 2003-03-07

För Patent- och registreringsverket  
For the Patent- and Registration Office

*Lina Oljeqvist*  
Lina Oljeqvist

Avgift  
Fee

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

**BEST AVAILABLE COPY**

## NOVEL FORMULATION

### Field of the invention

5 The present invention relates to specific excipients for powder formulations for oral and nasal inhalation.

### Background

10 The recent debate about transmissible spongiform encephalopathies (TSE) has highlighted the need for alternatives of excipients for use in pharmaceutical formulations. Compounds from an animal source should be abandoned in favour of compounds from the plant kingdom, or produced by effective and cheap synthetic procedures. Care has to be taken in  
15 the selection of new excipients since the drug delivery can be affected by the excipients through altered release of drug, bioavailability, solubility, stability, and dissolution rates leading to altered therapeutic activity and even an increase/decrease of unwanted side effects. Excipients are not always inert, and can show adverse toxicological findings by themselves or in drug formulations (see e.g. Br. J. Clin. Pharm (1988), 25, 283-287 and  
20 Resp. Med. (1990), 84, 345-348). An excipient should also fulfil all the physicochemical requirements as well as regulatory requirements necessary for a formulation in respiratory health care.

25 Sucrose is very moisture sensitive and will form cakes very easily when submitted to humidity and thereby being unsuitable as a constituent in formulations for inhalation. Its caries promoting effects make it also undesirable.

30 There are only two compounds presently on the market as carriers/diluents for inhalation formulations, namely lactose and glucose – both reducing saccharides. Besides, the main compound used is lactose which is isolated from the animal kingdom. A new excipient is therefore strongly needed.

35 WO95/00127 and WO95/00128 relate to polypeptide powders for inhalation, and disclose that non-reducing sugars such as raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol and starch may be suitable additives for the polypeptide powders.

US 6,004,574 describes a powder formulation for the administration of medically useful polypeptides, comprising a medically useful polypeptide with melezitose as diluent.

Forbes et al. describe in J. Aerosol Medicine (2000), 13(3), 281-288 the effects of pH, osmolality, and lactose on epithelial permeability cell layers. Mannitol flux was used to assess epithelial permeability.

- 5 R. Boucher (The University of North Carolina) has filed a patent application (WO 00/36915) describing treatment of chronic obstructive diseases by administering an osmotically active compound such as a salt, sugar, sugar alcohol or organic osmolyte to the afflicted airway surface. The list of compounds is extensive – however only monosaccharides are among the carbohydrates mentioned per se in the claims i.e.
- 10 osmotically active and thereby teaches away from the present invention.

It has been established that an osmotic gradient across the respiratory epithelium results in morphologic changes in the epithelial cells and a widening of intercellular spaces. No significant changes in FEV<sub>1</sub> has been observed after inhalation of solutions with an osmolality between 159-549 mOsm (Am. Rev. Resp. Dis. (1982), 125 (suppl) 61).

15

The above references have highlighted the problem in selecting a pharmaceutical excipient by studying the effect of different pH, osmolality and other parameters.

## 20 Description of the invention

In a first aspect the invention provides a crystalline excipient having its origin from the vegetable kingdom or being totally synthesized for use as a carrier/diluent in the preparation of pharmaceutical formulations for respiratory administration of micronised drugs by means of an inhaler characterized by

25 i) the excipient being a non-ionic compound, giving an iso-osmotic solution to saline when dissolved in water at a concentration of at least 5.5 % (w/v) and

ii) being at the most only slightly hygroscopic and non-reducing, provided that the excipient is not melezitose.

30 Preferably the excipient is present in a concentration of 7% or higher.

Medicaments suitable for inclusion in the formulation of the present invention are any which may be delivered by inhalation.

35 Suitable inhalable medicaments may include for example  $\beta$ 2-adrenoreceptor agonists for example salbutamol, terbutaline, rimiterol, fenoterol, reproterol, adrenaline, pirbuterol, isoprenaline, orciprenaline, bitolterol, salmeterol, formoterol, clenbuterol, procaterol, broxaterol, picumeterol, TA-2005 and malbuterol; anticholinergic bronchodilators for

example ipratropium bromide, oxitropium and its salts and tiotropium and its salts; glucocorticosteroids for example beclomethasone, fluticasone, budesonide, tipredane, dexamethasone, betamethasone, fluocinolone, triamcinolone acetonide, flunisolide, mometasone and 16, 17-acetals of pregnane derivatives, for example rofleponide palmitate and ciclesonide; anti-allergic medicaments for example sodium cromoglycate and nedocromil sodium; leukotriene antagonists for example, zafirlukast, montelukast, pranlukast, zileuton antihistamines for example terfenadine, cetirizine, loratadine and azelastine; antibiotics, ; pain control substances, for example morphine, codeine, pethidine, etc

Preferred medicaments that can be used in the formulations of the invention include formoterol, terbutaline, budesonide, a formoterol/budesonide combination e.g Symbicort®.

Combinations of medicaments may also be employed, for example formoterol/budesonide; formoterol/fluticasone; formoterol/mometasone; salmeterol/fluticasone; formoterol/tiotropium salts; zafirlukast/formoterol, zafirlukast/budesonide; montelukast/formoterol; montelukast/budesonide; loratadine/montelukast and loratadine/zafirlukast.

In the selection criteria for new excipients we have included possible pharmacodynamic effects based upon the osmolytic behaviour of each compound – the reason being an effect on ciliary activity and on the reology of the mucus. Hyperosmolarity also triggers release of mediators from human mast cells e.g. histamine (Am. Rev. Resp. Dis, 137 (1988), 606). A clinical study involving fifteen stable asthma patients inhaling lactose dry powder alone or salbutamol added (no dosage data given) has also been reported (Eur. Resp. J. (1995), 8 (Suppl. 19, 426S)) where lactose caused bronchoconstriction, but the effect was masked since the rapid acting drug was added to the dry powder. If  $\beta_2$ -agonists with slow onset or inhaled steroids are given with lactose dry powder as an excipient (carrier) substance this bronchoconstrictive effect could be a disadvantage, particularly with larger doses of excipient reaching the lung. However the effect is expected to be small.

More pronounced effects have been observed with mannitol. There are several reports where mannitol has been used to identify methacholine-responsive children with active asthma. Inhaled mannitol has been developed for bronchial challenge testing in adults, see e.g. Am. J. Respir. Crit. Care Med. 156 (1997). The most sensitive subjects were responding with a 15 % decrease in FEV1 at a dose of 2 mg!

The change in airway osmolarity has been described to contribute to the production of exercise-induced bronchoconstriction and the development of the late-phase response.

(Am. J. Resp. Crit. Care Med. 159 (1999), 634-640; 158 (1998), 1120-1126). It has also been reported that hyperosmolar saline has been used to narrow the airways (Am. Rev. Respir. Dis., 140 (1989), 593-597).

- 5 Hyperosmolarity also triggers release of mediators from human lung mast cells (e.g. histamine) and possibly neuropeptides e.g. substance P from sensory nerves, which have been shown to increase ciliary beat frequency thereby increasing the mucociliary clearance in asthmatic and healthy subjects (Eur. Resp. J. 10 (1997), 2449-2454).
- 10 Sandra Anderson has in a granted patent (US 5.817.028) described a method where a person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The amount of substance in the respiratory range ( $< 7 \mu\text{m}$ ) is from 1 to 100 mg, preferably
- 15 5 to 40 mg in the case of challenge testing for asthma or rhinitis.

When using a dry powder formulation a high local concentration of the components will be experienced. There is a risk to obtain a high local osmolarity causing bronchoconstriction or other adverse effects. The phenomena of osmolarity has not been a main issue in

20 powder formulations for inhalation and particularly not in the selection of excipients for such formulations. These drawbacks have now been eliminated by the present invention, namely by selecting a chemical stable, non-hygroscopic excipient so as to minimize the risk for high local osmolarity and at the same time eliminate the risk for TSE thereby being suitable for inhalation.

25 The main substance classes which can be used in the invention include sugar alcohols, di- and polysaccharides, amino acids, starch, cyclodextrines, polymers derived from glycolic and lactic acids and chitosans.

30 Table 1 shows the concentrations of different excipients giving iso-osmotic solutions to saline i.e. the higher concentration the less possibility for bronchoconstriction due to the excipient. We preferably select an excipient with a concentration of at least  $> 5.5 \%$ , preferably  $> 7 \%$  – compounds that could be regarded as weak osmolytic or non-osmolytic active compounds – teaching away from WO 00/36915. The selected concentration values

35 are based upon the clinical results presented for lactose and mannitol. The physiological condition is pH 7.4 and 276 mOsm.

Table 1. Osmolarity for an aqueous solution (%) giving an iso-osmotic solution with serum.<sup>1</sup>

	Maltitol	10
5	Lactose	9.8
	Sucrose	9.3
	Lactitol	7
	Ascorbic acid	5.9
	Dextrose (glucose)	5.5
10	Sorbitol	5.5
	Mannitol	5.1
	Fructose	5.1
	Oxymethazoline-HCl	4.9
	Galactose	4.9
15	Xylitol	4.6
	Lidocaine-HCl	4.4
	Sodium ascorbate	3.0
	Sodium chloride	0.9

20 The osmotic pressure is proportional to the concentration of the solute for nonelectrolytes. The osmotic pressures of solutions of different nonelectrolytes are proportional to the number of molecules in each solution. This means – when having the same amount in grams – a disaccharide will have about half the osmotic pressure as a monosaccharide, which could also be seen in table 1. This type of generalisations could not be used for  
25 electrolytes. All disaccharides (e.g. trehalose) would be expected to have an osmotic pressure corresponding to a solution of at least > 7 % and trisaccharides (e.g. melezitose, raffinose) needed higher concentration in order to be iso-osmotic with a saline solution. The carbohydrate myo-inositol would be expected to have a concentration of less than 5 % for iso-osmolytic activity with saline.

30 Maltitol is widely used in the pharmaceutical industry in the formulation of oral dosage form. It has properties which make it suitable as an inhalation excipient. For example it is noncariogenic (i.e. not effecting your teeth) bulk sweetener, as sweet as sucrose, well adapted as a diluent for the different oral dosage forms, wet granulations and hard coating.  
35 It is obtained from hydrogenated maltose syrup (from starch). Maltitol also has good thermal and chemical stability. It does not undergo browning reaction with amino acids, and absorbs moisture only at relative humidities of 89 % and above 20°C.

<sup>1</sup> The Pharmaceutical Codex – Principles and Practice of Pharmaceutics, 12<sup>th</sup> edition, London, 1994.

Maltitol is generally regarded as a nontoxic, nonallergenic and nonirritant material. A water solution is stable for at least 2 years at room temperature and pH 2-9! It is very stable at pH 4-9 even at higher temperatures. Maltitol is approved for food and non-  
5 parenteral pharmaceutical formulations in Europe and US.

$\alpha,\alpha$ -Trehalose dihydrate and  $\beta,\beta$ -trehalose tetrahydrate have similar dehydration-induced amorphisations as raffinose. It has been impossible to induce crystallisation of the amorphous anhydrous sugars. Several polymorphs of the anhydrous trehalose have been  
10 reported (JACS 120, 7893 (1998). Dehydration of the dihydrate occurs at 91-97 °C.

Lactitol as the monohydrate is nonhygroscopic and is stable under humid conditions. It is stable to heat and does not take part in the maillard reaction. Lactitol is very resistant to microbiological breakdown and fermentation. Lactitol is regarded as a nontoxic and  
15 nonirritant substance.

The excipients could be crystalline and be in the form of anhydrate or different hydrates, if any.

Small particles of either drugs or excipients are often made by techniques such as  
20 micronization or grinding. Most methods create particles which are amorphous or having partially amorphous structures. These particles are liable to change their structure when kept in an adverse environment e.g. high humidity for a certain period of time. The end result is often a decrease in dispersibility and a reduced dose delivered to the patient. One known process to resolving this problem is to reduce or eliminate the unstable amorphous  
25 phase by a conditioning process e.g. as described in EP 717 616 or US 5,874,063. The same process could be used also for larger carrier/diluent particles.

When the powder preparation of the present invention is intended for oral or nasal inhalation the formulation should consist of a) primary particles of active pharmacological  
30 drug particles having a diameter of less than 10  $\mu\text{m}$ , for example between 0.01 to 6  $\mu\text{m}$  or b) agglomerates of said particles.

The excipient in the formulation for oral or nasal inhalation may largely consist of particles having a diameter of less than about 10  $\mu\text{m}$  so that the resultant powder as a whole consists  
35 of optionally agglomerated primary particles having a diameter of less than about 10  $\mu\text{m}$ ; alternatively the excipient may largely consist of much bigger particles ("coarse particles") so that an "ordered mixture" may be formed between the active compound(s) and the excipient. The coarse particles may have a diameter of over 20  $\mu\text{m}$ . Preferably, the coarse

particles have a diameter of 60-800  $\mu\text{m}$ . A further alternative is a mixture of small particles below 10  $\mu\text{m}$  of the excipient together with the coarser particles in combination with the active compound(s).

- 5 There are many factors that influence powder behaviour e.g. particle size and distribution, shape, crystallinity, charge density, chemical composition and environmental humidity. To cope with this, rigorous control of starting material and processes is required. Commonly used size reduction techniques including jet mill micronization, produce particles which may have regions of partially amorphous structure and which have an irregular shape.
- 10 Such particles have a high surface energy and are liable to structural changes which may even include sintering if exposed to humidity during storage or use. The amorphous structure may be eliminated by subjecting the particles to a controlled conditioning process.
- 15 Loose particle agglomerates are formed as fine particles are exposed to movements within a powder bed. The ability of a powder to form agglomerates without additional binders is closely bound up with the adhesive forces. The agglomerates, as well as the ordered mixture, should be such as to give a sufficient adhesion force to hold the small drug particles during manufacturing, transportation etc but small enough to be broken during
- 20 inhalation of the powder. A hygroscopic compound will strongly decrease this deagglomeration process and when the powder has been exposed to a high humidity. The result will be a low respirable dose delivered from the inhaler. The carrier particles should therefore be as less hygroscopic as possible and it is the object of this invention to link also this property to a selected excipient. The selected excipients according to the invention
- 25 should be only slightly hygroscopic i.e. no moisture increase occurring below 80 % relative humidity and the increase in moisture content, when the excipient is stored at 80 % relative humidity or above for 1 week, does not exceed 40 % according to the proposition by the Working Party "Guide for the technical content of monographs" of the European Pharmacopoeia Commission (Pharmeuropa, vol. 4, no 3 September 1992, pages 228-230).
- 30 In order to eliminate chemical interactions as much as possible the excipient should be non-reducing e.g. not react when tested in Fehling's solution (Method of analysis, see Ph Eur 2001).
- 35 In a further aspect the invention provides a pharmaceutical formulation for respiratory administration comprising a drug and excipient characterized in that
- i) the excipient is a non-ionic compound, giving an iso-osmotic solution to saline when dissolved in water at a concentration of at least 5.5 % (w/v) and
  - ii) being at the most only slightly hygroscopic and non-reducing,



provided that the excipient is not melezitose..

100643

**Claims:**

1. A crystalline excipient having its origin from the vegetable kingdom or being totally synthesized for use as a carrier/diluent in the preparation of pharmaceutical formulations for respiratory administration of micronised drugs by means of an inhaler characterized by  
5 i) the excipient being a non-ionic compound, giving an iso-osmotic solution to saline when dissolved in water at a concentration of at least 5.5 % (w/v) and  
ii) being at the most only slightly hygroscopic and non-reducing,  
provided that the excipient is not melezitose..

10 2. An excipient according to claim 1, wherein the concentration of the excipient is equal or higher than 7 % (w/v).

15 3. An excipient according to any preceding claim, wherein the excipient consists of sugar alcohols, di- and polysaccharides, amino acids, starch, cyclodextrines, polymers derived from glycolic and lactic acids and chitosans.

4. An excipient according to any preceding claim, wherein the excipient is selected from the group consisting of maltitol, lactitol, melezitose and trehalose.

20 5. An excipient according to any preceding claim, wherein the excipient is maltitol.

25 6. A method of selecting a crystalline excipient having its origin from the vegetable kingdom or being totally synthesized for use as a carrier/diluent in the preparation of pharmaceutical formulations for respiratory administration of micronised drugs by means of an inhaler comprising

i) selecting an excipient that is a non-ionic compound, giving an iso-osmotic solution to saline when dissolved in water at a concentration of at least 5.5 % (w/v) and  
ii) being at the most only slightly non-hygroscopic and non-reducing.

30 7. A pharmaceutical formulation for respiratory administration comprising a drug and excipient characterized in that

35 i) the excipient is a non-ionic compound, giving an iso-osmotic solution to saline when dissolved in water at a concentration of at least 5.5 % (w/v) and  
ii) being at the most only slightly hygroscopic and non-reducing,  
provided that the excipient is not melezitose..

8. A pharmaceutical formulation for respiratory administration comprising a drug and maltitol excipient.

**ABSTRACT**

The present invention relates to specific excipients for powder formulations for oral and  
5 nasal inhalation.

10

15

20

25

11  
12  
13  
14  
15  
16  
17  
18  
19  
20

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**